A. Arcocha
YOU?
Author Swipe
View article: Multimodal prehabilitation to prevent loss of cardiorespiratory fitness in patients with locally advanced lung cancer undergoing chemoimmunotherapy: protocol for a non-randomized multicentre study
Multimodal prehabilitation to prevent loss of cardiorespiratory fitness in patients with locally advanced lung cancer undergoing chemoimmunotherapy: protocol for a non-randomized multicentre study Open
ClinicalTrials.gov; NCT05636969.
View article: Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study) Open
Background: Geographical variations in the frequency of oncogenic driver alterations in non-small cell lung cancer (NSCLC) are observed worldwide, likely influenced by genetic and environmental factors. Radon, a leading cause of lung cance…
View article: 48P Real-world clinical utility of next-generation sequencing ctDNA for patients with advanced lung squamous cell carcinoma
48P Real-world clinical utility of next-generation sequencing ctDNA for patients with advanced lung squamous cell carcinoma Open
Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) can identify a wide spectrum of genomic alterations (GAs), guiding treatment decisions in patients (pts) with non-small cell lung cancer (NSCLC), especially with adenocarcin…
View article: 178P Germline testing in non-small cell lung cancer (NSCLC): Real-world impact of the discovery of germline pathogenic variants (PGV) in the INHERITY LC (ILC) study
178P Germline testing in non-small cell lung cancer (NSCLC): Real-world impact of the discovery of germline pathogenic variants (PGV) in the INHERITY LC (ILC) study Open
It is estimated that around 8% of NSCLC are linked to genetic predisposition. However, there is no criteria for study on Genetic Counseling Units (GCU). In the ILC study we identified 11% of PGVs in patients (pts) with NSCLC. Here, we repo…
View article: A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC
A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC Open
Background: The role of perfusion computed tomography (pCT) in detecting changes in tumor vascularization as part of a response to antiangiogenic therapy in non-small cell lung cancer (NSCLC) remains unclear. Methods: In this prospective p…
View article: Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions Open
The cobas® EGFR Test provides a semiquantitative index (SQI) that reflects the proportion of mutated versus wild-type copies of the EGFR gene in plasma. The significance of SQI as an indirect measure of the variant allele frequency (VAF) o…
View article: Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice
Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice Open
The study indicates that cfDNA analysis in plasma for EGFR testing by RT-PCR is an accurate and fast method to initially stratify NSCLC patients in a real-world clinical setting. However, the SQI has limited clinical value. The cfDNA conce…
View article: Multiplex RNA‐based detection of clinically relevant <i>MET</i> alterations in advanced non‐small cell lung cancer
Multiplex RNA‐based detection of clinically relevant <i>MET</i> alterations in advanced non‐small cell lung cancer Open
MET inhibitors have shown activity in non‐small‐cell lung cancer patients (NSCLC) with MET amplification and exon 14 skipping ( METΔex14) . However, patient stratification is imperfect, and thus, response rates have varied widely. Here, we…
View article: Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients
Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients Open
Targeted therapies are a new paradigm in lung cancer management. Next-generation sequencing (NGS) techniques have allowed for simultaneous testing of several genes in a rapid and efficient manner; however, there are other molecular diagnos…
View article: Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients
Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients Open
Personalized medicine is nowadays a paradigm in lung cancer management, offering important benefits to patients. This study aimed to test the feasibility and utility of embedding two multiplexed genomic platforms as the routine workup of a…